Tdap Vaccine Administration
ApprovedVaccine
Tdap Vaccine Administration is one of 39 biologic programs targeting Preeclampsia. It is currently in Approved.
1
Indications
2
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
117 competitors in Preeclampsia
#DrugCompanyPhaseTrials
1Plaquenil
Alnylam PharmaceuticalsPhase 3
Folvite
Eli LillyPhase 3
Nexium
DDexcel Pharma Technologies Ltd.
Phase 3
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Pitocin
RRetrophin
Phase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Glucophage
Boehringer IngelheimPhase 3
Low-Molecular-Weight Heparin
Daiichi SankyoPhase 3
Crestor
AstraZenecaPhase 2
No Drug
Daiichi SankyoPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Preeclampsia1 trial
Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
Unknown status·—·Phase 4·NCT04424693·1,600 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tdap Vaccine Administration. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details